Ischemic heart disease is a common consequence of coronary artery disease (CAD), which is primarily driven by atherosclerosis, a chronic inflammatory ...

Cytotoxic T cells are an important component of the ... molecular mechanism that leads to the faster and stronger activation of cells with nuclear invaginations: "Their special cellular ...

The FDA cleared the investigational new drug (IND) application for EVM14. EVM14 is an off-the-shelf tumor-associated antigen ...

Immunostimulant therapy using agonistic cytokines or activating antibodies has been associated with off-target side effects, failure to preferentially activate cytotoxic lymphocytes (CTLs) over ...

They include cytotoxic T cells, which are important for killing ... VDAC2 deficiency elicits uncontrolled IFNγ-induced BAK activation and mitochondrial damage for improved cancer therapy.

A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...

In March 2025, Juventas Cell Therapy Ltd. conducted a phase Ib/II trial to evaluate the safety and efficacy of CNCT19 ...

Aptevo Therapeutics (APVO) provided an overview of solid tumor anti-cancer compound APVO603, currently in preclinical development for the ...

Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 BASEL, Switzerland, ...